Study Design   |   ORR   |   TTF   

 

Uncommon EGFR pooled analysis: comprehensive data from patients with uncommon mutations receiving afatinib

The pooled analysis assessed the clinical outcomes of 693 EGFR M+ NSCLC patients harboring uncommon mutations that were treated with afatinib. Published data were obtained from: LUX-Lung 3 & 6 randomised controlled trials, LUX-Lung 2 single arm Phase ll clinical trial, compassionate use and expanded access programmes, Phase lllb trials, real-world trials and series/reports. Clinical outcomes by individual genotype were generated into a searchable database. 

Afatinib demonstrated clinical activity in patients with NSCLC with major uncommon and compound EGFR mutations, with broad activity in other uncommon EGFR mutations and some exon 20 insertions.*

 

Read the original publication: Afatinib for the treatment of NSCLC Harboring Uncommon EGFR Mutations:
a database of 693 cases


Study design

Data in EGFR-TKI naive patients and EGFR-TKI pre-treated patients with uncommon EGFR mutations who received afatinib were included, using prospectively collected published data since the beginning of clinical development of afatinib by Boehringer Ingelheim medical information as well as from a systematic literature review. All cases with ORR and TTF outcomes were included in the analysis.1

Overview of data selection in the Uncommon EGFR pooled analysis1

Overview of data selection in the Uncommon EGFR pooled analysis[1]

Adapted from Yang JCH, et al. 2020.

*T790M, exon 20 insertion and major uncommon mutation negative.


ORR values of up to 78.3% were reported in the Uncommon EGFR pooled analysis for patients treated with afatinib1

Response rates in patients with major and compound mutations1*

Response rates in patients with major and compound mutations

Data taken from JCH, et al. 2020.

*Compound mutations were defined as cases where at least 2 uncommon mutations were present with or without a common mutation.1

Response rates in patients with specific mutations1

Response rates in patients with specific mutations

Data taken from Yang JCH, et al. 2020.


TTF durations of up to 16.6 months were reported in the Uncommon EGFR pooled analysis1

  • TTF responses to afatinib treatment were seen in patients with major uncommon mutations1

TTF in patients with major uncommon and compound EGFR mutations1*

TTF in patients with major uncommon and compound EGFR mutations

Data taken from Yang JCH, et al. 2020.

*Comound mutations were defined as cases where at least 2 uncommon mutations were present with or without a common mutation.

TTF in patients withspecific EGFR mutations

TTF in patients withspecific EGFR mutations

Data taken from Yang JCH, et al. 2020.


References

1
Yang JCH, et al. J Thorac Oncol 2020. DOI: 10.1016/j.jtho.2019.12.126.